Vistin Pharma ASA (LTS:0RAM) Cyclically Adjusted Revenue per Share: kr9.46 (As of Mar. 2026)


LTS:0RAM Vistin Pharma ASA LTS:0RAM
77 GF Score
Price kr20.70
GF Value kr25.61
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Vistin Pharma ASA Cyclically Adjusted Revenue per Share?

Vistin Pharma ASA LTS:0RAM 77 Cyclically Adjusted Revenue per Share is kr9.46 as of Mar. 2026. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Vistin Pharma ASA's adjusted revenue per share for the three months ended in Mar. 2026 was kr2.525. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is kr9.46 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Vistin Pharma ASA's average Cyclically Adjusted Revenue Growth Rate was -8.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-06), Vistin Pharma ASA's current stock price is kr20.70. Vistin Pharma ASA's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was kr9.46. Vistin Pharma ASA's Cyclically Adjusted PS Ratio of today is 2.19.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vistin Pharma ASA was 2.80. The lowest was 2.03. And the median was 2.33.


Vistin Pharma ASA  (LTS:0RAM) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Vistin Pharma ASA's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=20.70/9.46
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Vistin Pharma ASA was 2.80. The lowest was 2.03. And the median was 2.33.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Vistin Pharma ASA Cyclically Adjusted Revenue per Share Related Terms


Vistin Pharma ASA Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Vistin Pharma ASA's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistin Pharma ASA Cyclically Adjusted Revenue per Share Chart

Vistin Pharma ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 10.33 9.79

Vistin Pharma ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.56 10.29 10.07 9.79 9.46

LTS:0RAM vs ZTS, UTHR, VTRS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vistin Pharma ASA Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Vistin Pharma ASA's Cyclically Adjusted PS Ratio falls into.


LTS:0RAM
77GF Score
Vistin Pharma ASA LTS:0RAM
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistin Pharma ASA Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Vistin Pharma ASA's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=2.525/141.0300*141.0300
=2.525

Current CPI (Mar. 2026) = 141.0300.

Vistin Pharma ASA Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 3.140 103.800 4.266
201609 2.192 104.200 2.967
201612 1.919 104.400 2.592
201703 2.560 105.000 3.438
201706 2.689 105.800 3.584
201709 2.781 105.900 3.704
201712 2.437 106.100 3.239
201803 3.062 107.300 4.025
201806 1.551 108.500 2.016
201809 1.141 109.500 1.470
201812 0.753 109.800 0.967
201903 0.845 110.400 1.079
201906 1.378 110.600 1.757
201909 1.534 111.100 1.947
201912 1.259 111.300 1.595
202003 1.385 111.200 1.757
202006 1.647 112.100 2.072
202009 1.242 112.900 1.551
202012 1.436 112.900 1.794
202103 1.597 114.600 1.965
202106 1.507 115.300 1.843
202109 1.417 117.500 1.701
202112 1.698 118.900 2.014
202203 0.749 119.800 0.882
202206 1.556 122.600 1.790
202209 2.068 125.600 2.322
202212 2.114 125.900 2.368
202303 2.276 127.600 2.516
202306 2.407 130.400 2.603
202309 2.705 129.800 2.939
202312 2.497 131.900 2.670
202403 2.343 132.600 2.492
202406 2.392 133.800 2.521
202409 2.387 133.700 2.518
202412 2.564 134.800 2.682
202503 2.594 136.100 2.688
202506 2.654 137.800 2.716
202509 2.454 138.500 2.499
202512 2.497 139.100 2.532
202603 2.525 141.030 2.525

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of kr9.46 mean?
Vistin Pharma ASA (LTS:0RAM) has a Cyclically Adjusted Revenue per Share of kr9.46 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vistin Pharma ASA and its competitors.
Is Vistin Pharma ASA's Cyclically Adjusted Revenue per Share too high?
Vistin Pharma ASA's current Cyclically Adjusted Revenue per Share is kr9.46. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Vistin Pharma ASA's Cyclically Adjusted Revenue per Share of kr9.46 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Vistin Pharma ASA and its competitors. Vistin Pharma ASA's current Cyclically Adjusted Revenue per Share is kr9.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is kr9.46. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Cyclically Adjusted Revenue per Share is kr9.46 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?

Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued. The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61. GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.

Key valuation signals for LTS:0RAM:

  • Cyclically Adjusted Revenue per Share: kr9.46
  • GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Vistin Pharma ASA Business Description

Address Ostensjoveien 27, P.O. Box 6735 Etterstad, Oslo, NOR, 0661
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score

Get the complete analysis for LTS:0RAM

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr20.70
Price
kr25.61
GF Value